Clinical Trial Inclusivity, Diversity, and Equity in Action

In 2022, FDA’s Draft Guidance on Diversity Plans and passage of the Food and Drug Omnibus Reform Act (FDORA) significantly changed the landscape for diversity and inclusion in clinical trials. In this DIA Global Annual Meeting 2023 interview, Curavit President and Co-Founder Dave Hanaman and Clinical Research Business Development Manager Natalia Husby discuss Curavit’s new Inclusivity, Diversity, and Equity in Action (IDEA) service offering with DIA Scientific Programs Associate Director Tamei Elliott. Look for this and similar content in your DIA Global Forum.